Drug development



Aclaris Therapeutics
Public Companies

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital

- by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is making strategic moves, announcing several updates this week including promising trial results, a shift in drug development focus, and a significant …

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital Read More
Virpax Pharmaceuticals
Products and Services / Research

Virpax Pharmaceuticals’ Envelta Set for Human Trials Following FDA Review: A Potential Game-Changer in Pain Management

- by Timothy Alexander

BERYWN, PA — In a significant move that promises to reshape the future of pain management, Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its intent to submit an Investigational New …

Virpax Pharmaceuticals’ Envelta Set for Human Trials Following FDA Review: A Potential Game-Changer in Pain Management Read More

Annovis Bio
Products and Services / Research

Annovis Bio’s Buntanetap Trial for Alzheimer’s Disease Gets Green Light from DSMB: A Positive Step Forward

- by Timothy Alexander

BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS), a biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases, recently announced a significant milestone in its clinical trial journey. The …

Annovis Bio’s Buntanetap Trial for Alzheimer’s Disease Gets Green Light from DSMB: A Positive Step Forward Read More